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An effective vaccine against sexual transmission of human immunodeficiency virus (HIV) should elicit both systemic and
mucosal immune responses. In this study, to examine the possibility of using an attenuated virus for mucosal immunization,
four female macaques were intranasally or intravenously administered with a chimeric simian-human immunodeficiency virus
with a deleted nef gene (SHIV-dn). Although all the monkeys had anti-HIV-1 antibodies with neutralizing activity in the plasma,
the intranasally immunized monkeys had much higher levels of HIV-1 Env-specific IgG and IgA antibodies in mucosal
secretions compared with the intravenously immunized monkeys. Moreover, three of four intranasally immunized monkeys
were completely protected from intravaginal challenge with a pathogenic virus, SHIV-89.6P, whereas only one intravenously
immunized monkey was protected. Thus, intranasal immunization of an attenuated virus can induce the protective efficacyon.INTRODUCTION
The mucosal surfaces of the cervix, vagina, and rec-
tum are the primary sites of contact for sexually trans-
mitted viruses, such as human papillomavirus, herpes
simplex virus, and human immunodeficiency virus (HIV).
To be effective, vaccines for HIV must provide sufficient
protection against mucosal infection of HIV, since the
local immune responses at mucosal surfaces and tis-
sues have an important role in preventing the entry of
sexually transmitted viruses. This is supported by find-
ings that cell-mediated immunity and mucosal IgA have
protective roles in HIV-seronegative individuals exposed
to HIV (Kaul et al., 1999; Mazzoli et al., 1997). HIV-specific
immune responses, such as anti-HIV antibodies and
cytotoxic T lymphocytes (CTLs), are found in vaginal
secretions and in the cervix of HIV-infected women (Mu-
sey et al., 1997; Lu et al., 1993; Belec et al., 1989).
Similarly, in female macaques infected with simian im-
munodeficiency virus (SIV), the genital secretions and
vaginal mucosa were confirmed to contain SIV-specific
antibodies and CTLs (Miller et al., 1992; Lohman et al.,
1995). Thus, the presence of local immune responses
suggests that an approach to induce both systemic and
1 To whom correspondence and reprint requests should be ad-
dressed at Laboratory of Viral Pathogenesis, Institute for Virus Re-© 2002 Elsevier Science (USA)
All rights reserved.mucosal immunity might be required for protection
against HIV.
To induce an antigen-specific immune response in the
reproductive tract, the most effective immunization route
for delivering an antigen must be selected. Vaccines that
are administered parenterally can induce antigen-spe-
cific systemic immune responses, but they are not effec-
tive in inducing mucosal immunity. In contrast, mucosally
applied antigens have been shown to effectively induce
both systemic and mucosal immunity (Nardelli et al.,
1999; Crotty et al., 1999; Sedlik et al., 1999; Kozlowski et
al., 1997; Gallichan and Rosenthal, 1996). Attempts to
generate an antigen-specific mucosal immune response
have included tracheal, gastric, nasal, rectal, and vaginal
administration of various vaccine candidates, such as
DNA and inactivated virus. Several studies have demon-
strated that mucosal immunity could be generated in the
genital tract by intranasal immunization of an antigen
(Dupuy et al., 1999; Klavinskis et al., 1999; Balmelli et al.,
1998; Imaoka et al., 1998; Staat et al., 1996, 1997). Al-
though the exact mechanism of this immunization for the
induction of mucosal immunity in the reproductive tissue
is unclear, it appears to be related to stimulation of
immunocompetent cells in nasopharyngeal-associated
lymphoreticular tissue (NALT).
The macaque model using nonhuman primate lentivi-
ruses is commonly used to determine the protective
effects of vaccine candidates against viral infection. At-against intravaginal infection. © 2002 Elsevier Science (USA)
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shown to enable macaque monkeys to resist infection
when challenged with the intact virus (Wyand et al., 1999;
Johnson et al., 1999; Connor et al., 1998; Daniel et al.,
1992). Moreover, chimeric simian-human immunodefi-
ciency viruses (SHIVs) have also been constructed in
several laboratories and can be infectious both intrave-
nously and mucosally to macaque monkeys (Harouse et
al., 1998; Joag et al., 1997; Karlsson et al., 1997; Shibata
et al., 1997; Lu et al., 1996; Reimann et al., 1996b; Kuwata
et al., 1995). These chimeric viruses, in which the HIV-1
envelope gene is inserted into the envelope region of the
SIV genome, are useful for defining the role of envelope
glycoproteins in viral pathogenesis and for evaluating
HIV-1 env-based vaccine candidates. Other studies have
shown that immunization of monkeys with attenuated
SHIVs could prevent infection from challenge viruses
and arrest the development of the disease (Ui et al.,
1999a; Joag et al., 1998; Igarashi et al., 1997; Miller et al.,
1997). A better understanding of how SHIVs provide
protective immunity against infection should help in the
design of HIV vaccines.
The objective of this study was to examine the possi-
bility of inducing systemic and mucosal immunity with an
attenuated virus. Specifically, we attempted to determine
whether intranasal immunization of a nef-deleted SHIV
(SHIV-dn) could induce more protective effects against
intravaginal infection of a pathogenic virus by compari-
son with intravenous immunization of SHIV-dn.
RESULTS
Intranasal and intravenous immunization of female
macaque monkeys with SHIV-dn
Four female macaque monkeys (MM171, MM187,
MM206, and MM207) were intranasally administered
with SHIV-dn. All monkeys were successfully infected, as
shown by the detection of proviral DNAs of SHIV-dn in
PBMCs in two of the monkeys at 2 weeks postinocula-
tion (w.p.i.), and in the other two at 4 w.p.i. (Table 1). The
viral DNAs of SHIV-dn were sporadically detected in
PBMCs, but were not observed in cells in the vaginal
wash (VWCs) during the observation period. Moreover,
the infectious viruses were not isolated from either
PBMCs or VWCs obtained from any of the monkeys by
coculture with M8166. Thus, intranasal immunization
with SHIV-dn could provide continuous stimulation for
the induction of antigen-specific immune response in
macaque monkeys.
Intravenous infection with SHIV-dn was also success-
ful in all four monkeys. In SHIV-dn-intravenously immu-
nized monkeys (MM162, MM163, MM169, and MM170),
the viral DNAs of SHIV-dn were sporadically detected in
PBMCs and the infectious viruses were isolated from
PBMCs of all monkeys at 2 w.p.i. However, these mon-
keys showed no clinical sign of the disease and no
detection of SHIV-dn just before challenge, at 54 w.p.i.
The results of intravenous infection with SHIV-dn agreed
with the results which had been previously reported (Ui
et al., 1999a).
HIV-1 Env-specific antibody responses in plasma of
the SHIV-dn-immunized monkeys
Antibody levels in the plasma of the SHIV-dn-intrana-
sally and -intravenously immunized monkeys were ex-
amined using the PA method. Antibodies to HIV-1 Env
were first detected in the plasma of SHIV-dn intranasally
immunized monkeys at 8 to 12 w.p.i. (Fig. 1A). Antibody
titers gradually increased in all the monkeys and just
before challenge were detected at serial dilutions of 8192
or 16,384. Moreover, all the monkeys had SIV Gag-spe-
cific antibodies as well as HIV-1 Env antibodies in the
plasma and also neutralizing antibodies at titers of 1:40
to 1:640 to the parental virus, SHIV-NM-3rN, but not the
heterologous virus, SHIV-89.6P. For comparison, the
SHIV-dn-intravenously immunized monkeys also had
high titers of antibody response in the plasma (Fig. 1B).
Thus, both intranasal and intravenous immunization with
SHIV-dn could induce high antigen-specific antibody re-
sponses in plasma.
TABLE 1
Virological Status of SHIV-dn-Intranasally Inoculated Monkeys
Monkey
Weeks postinoculation
0 2 4 8 12 20 29a 40 52
MM171
PCR (PBMC)         
(VWC)         
Virus isolationb (PBMC)         
(VWC)         
MM187
PCR (PBMC)         
(VWC)         
Virus isolationb (PBMC)         
(VWC)         
MM206
PCR (PBMC)       
(VWC)       
Virus isolationb (PBMC)       
(VWC)       
MM207
PCR (PBMC)       
(VWC)       
Virus isolationb (PBMC)       
(VWC)       
Note. VWC, vaginal wash cells.
a In MM206 and MM207, the results about samples at 26 weeks
postinoculation are shown.
b Virus isolation was performed by coculture with human T cell line,
M8166.
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HIV-1 Env-specific antibody responses in mucosal
secretions of the SHIV-dn-immunized monkeys
We next examined whether HIV-1 Env-specific antibod-
ies were also induced in mucosal sites of the intrana-
sally immunized monkeys. In all of the monkeys intrana-
sally administered with SHIV-dn, HIV-1 Env-specific IgG
and/or IgA antibodies were detected in the vaginal wash
(VW), although the antibody response differed among the
individuals (Figs. 2A and 2E). One monkey, MM207, had
both HIV-1 Env-specific IgG and IgA antibodies in the VW.
The neutralizing activities of the VW were hardly de-
tected in any monkeys because VW samples used in this
assay were consistent with the low concentration of total
immunoglobulin (3.3–23 g/ml of IgG, 0.1–1.1 g/ml of
IgA, and 0.3–2.6 g/ml of IgM). However, the neutralizing
antibodies of the VW of MM171 slightly cross-reacted
with both SHIV-NM-3rN and SHIV-89.6P. Similarly, the
fecal wash (FW) from all the monkeys contained HIV-1
Env-specific IgG and/or IgA antibodies (Figs. 2B and 2F).
Low levels of HIV-1 Env-specific antibodies were seen in
the oral wash (OW) during the observation period (Figs.
2C and 2G). Thus, intranasal immunization could induce
antigen-specific antibody responses not only in plasma
but also in mucosal secretions. While antigen-specific
antibody responses were induced in mucosal secretions
of the intranasally immunized monkeys, HIV-1 Env-spe-
cific IgG and IgA antibodies were not detected or were
detected at low levels in the VW of the intravenously
immunized monkeys (Figs. 2D and 2H). Taken together,
these findings suggested that intranasal administration
of SHIV-dn is an effective mucosal immunization regimen
for the induction of antigen-specific antibody response
with neutralizing activity.
Cellular immune responses in the SHIV-dn-inoculated
monkeys
In addition to the detection of HIV-1 Env-specific anti-
bodies in the plasma and mucosal secretions, CTL ac-
tivities against HIV-1 Env or SIV Gag were assayed for
SHIV-dn-immunized monkeys (Table 2). In SHIV-dn-intra-
nasally immunized monkeys, the HIV-1 Env-specific
CTLs were detected at 3.0% in MM206 and 1.3% in
MM207, and SIV Gag-specific CTLs were detected at
6.2% in MM187. The low levels of NK activities (1.7–7.1%)
were also detected in all four monkeys. In SHIV-dn-
intravenously immunized monkeys, neither CTL activities
against HIV-1 Env nor SIV Gag were detected, although
NK activities (22.2–34.9%) were detected in all four mon-
keys. Thus, both intranasal and intravenous immuniza-
tion with an attenuated virus induced a weak cellular
immune response.
Intravaginal challenge of the SHIV-dn immunized
monkeys with SHIV-89.6P
To evaluate the protective effects provided by intrana-
sal immunization, a pathogenic virus, SHIV-89.6P, was
intravaginally challenged to the SHIV-dn-intranasally im-
munized monkeys. In the two unimmunized monkeys
(MM158 and MM164) that were infected with SHIV-89.6P,
the viral RNA of SHIV-89.6P in plasma increased to about
108 copies/ml at 2 or 3 w.p.i. (Fig. 3A). The proviral DNAs
FIG. 1. HIV-1 specific antibody responses in plasma obtained from (A) SHIV-dn-intranasally immunized monkeys, MM171, MM187, MM206, and
MM207, and (B) intravenously immunized monkeys, MM162, MM163, MM169, and MM170. Antibodies to HIV-1 Env in plasma were measured by the
PA method. Data are indicated as the titer of serial dilution.
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of SHIV-89.6P were first detected in PBMCs at 1 w.p.i. in
MM164 and at 2 w.p.i. in MM158, and they continued to
be detected in PBMCs (Table 3). The infectious viruses
were also isolated in these two monkeys.
On the other hand, two of the SHIV-dn-intranasally
immunized monkeys (MM171 and MM187), which were
challenged at 52 w.p.i., and one monkey (MM207) which
was challenged at 27 w.p.i., were completely protected
against SHIV-89.6P intravaginal infection (Table 3). No
detection of viral RNAs in the plasma of these monkeys
verified the complete protection against SHIV-89.6P vag-
inal challenge (Fig. 3A). In addition, neither proviral DNAs
nor infectious viruses of SHIV-89.6P were detected in
PBMCs or VWCs from these monkeys during the 16-
week period after the challenge (Table 3). Moreover,
proviral DNAs of SHIV-89.6P were not detected in the
intestinal lymph nodes at 1 week postchallenge (w.p.c.)
and in the inguinal lymph nodes at 2 w.p.c., obtained by
biopsy. The number of CD4 cells in the SHIV-dn-intra-
nasally immunized monkeys remained within the normal
range observed before the challenge, while those in the
unimmunized monkeys dramatically decreased to about
1/10 of the preinfection level at 3 w.p.c. (Fig. 4A).
However, MM206, which was challenged at 26 w.p.i.,
became infected with SHIV-89.6P. In MM206, proviral
DNAs of SHIV-89.6P were first detected in PBMCs and
the inguinal lymph node at 2 w.p.c., and the infectious
virus was isolated from both of them (Table 3). Proviral
TABLE 2
Cell-mediated Immune Responses of SHIV-dn-immunized Monkeys Just Before Challenge
Monkey
Cellular immune responses (%)a
Monkey
Cellular immune responses (%)a
CTL NK activity CTL NK activity
SIV gag/HIV-1 envb SIV gag/HIV-1 envb
Intranasal immunization Intravenous immunization
MM171 ND/ND 3.0 MM162 0/0 24.3
MM187 6.2/0 7.1 MM163 0/0 23.2
MM206 0/3.0 4.2 MM169 0/0 34.9
MM207 0/1.3 1.7 MM170 0/0 22.2
Note. ND, not done.
a Effector/target cell ratio  100:1.
b B lymphoblastoid cell lines which were infected with recombinant vaccinia virus expressing SIVmac239 Gag or HIV-1 IIIB Env were used as target
cells.
FIG. 3. SHIV-89.6P-specific viral RNA loads in plasma of the SHIV-dn-immunized monkeys after intravaginal challenge. (A) Plasma viral RNA loads
in the SHIV-dn-intranasally immunized monkeys; MM171 (open circles), MM187 (open squares), MM206 (open triangles), and MM207 (open
diamonds). (B) Plasma viral RNA loads in the SHIV-dn-intravenously immunized monkeys; MM162 (open circles), MM163 (open squares), MM169
(open triangles) and MM170 (open diamonds). MM158 (closed circles) and MM164 (closed squares) which were unimmunized with SHIV-dn were
intravaginally inoculated with SHIV-89.6P. The detection limit of this assay was 103 copies/ml.
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DNAs of SHIV-89.6P were also detected in VWCs at
2 w.p.c. Nevertheless, in MM206, the viral RNA load of
the challenge virus in the plasma was only 1/1000 of the
peak value in the naive control (Fig. 3A), and the CD4
cell counts in PBMCs were not depleted (Fig. 4A).
Moreover, the protective effect of intranasal immuni-
zation with SHIV-dn was compared with that of intrave-
nous immunization. In the SHIV-dn-intravenously immu-
nized monkeys, the viral RNAs of SHIV-89.6P were de-
tected in plasma of three monkeys (MM162, MM163, and
MM170) but not in one monkey (MM169) (Fig. 3B). How-
ever, the viral RNA loads in three infected monkeys were
lower than that in the unimmunized monkeys, and none
of the monkeys showed the decline of CD4 T cell
counts in PBMCs (Fig. 4B). Although three of four mon-
keys could not be completely protected against intravag-
inal infection with SHIV-89.6P, only one monkey (MM169)
was not infected with SHIV-89.6P, showing protection
against intravaginal challenge.
Thus, three of four intranasally immunized monkeys
were completely protected against intravaginal infection
with SHIV-89.6P, whereas only one of four intravenous
immunized monkeys was protected. In summary, intra-
nasal immunization with SHIV-dn induced effective pro-
tective immunity against vaginal infection, as well as or
even more than, intravenous immunization.
DISCUSSION
This study demonstrated that intranasal immunization
of an attenuated virus provided effective protection
against intravaginal infection of a heterologous patho-
genic virus. Three of four intranasally immunized mon-
keys were completely protected against intravaginal in-
fection of SHIV-89.6P, as shown by the failure to detect
SHIV-89.6P and an absence of a decline of CD4 cells.
These monkeys had antibodies to HIV-1 both in plasma
and in vaginal secretions. The levels of IgG antibodies to
HIV-1 Env in vaginal secretions were higher in these
monkeys than in the other monkeys that were not pro-
tected from the challenge, although antibody titers in the
plasma were high in all the monkeys. Previous studies
also detected antigen-specific antibodies in vaginal se-
cretions of the SIV antigen-vaccinated monkeys (Lu et al.,
1998; Marx et al., 1993; Lehner et al., 1992). However,
little is known about whether antibodies detected in
mucosal secretions could directly block mucosally trans-
mitted viruses. Recently, some researchers reported that
passive administration of an anti-HIV neutralizing IgG to
macaque monkeys prevented vaginal transmission of a
pathogenic SHIV and suggested that neutralizing anti-
bodies protected against vaginal infection (Parren et al.,
2001; Mascola et al., 2000). In our study, neutralizing
antibodies against the parental virus, SHIV-NM-3rN,
were detected in the plasma of all the monkeys and in
the vaginal wash of one monkey (MM171). Moreover, in
MM171, the neutralizing antibodies in the vaginal wash
suppressed the replication of a heterologous virus, SHIV-
89.6P. This observation and the fact that the challenge
virus, SHIV-89.6P, was not detected in VWCs of three
monkeys raised the possibility that neutralizing antibod-
ies in vaginal secretions are the first line of defense
against the virus by preventing it from penetrating the
vaginal membrane.
One intranasally immunized monkey (MM206) became
infected with SHIV-89.6P after the intravaginal challenge.
TABLE 3
Virological Status of SHIV-89.6P-Intravaginally Inoculated Monkeys
Monkey
Weeks postinoculation
0 1 2 3 4 8 12
MM171 (i.nasal)
PCR (PBMC)a  dn (dn)c dn (dn)d  dn  
(VWC)       
Virus load (PBMC)b       
(VWC)       
MM187 (i.nasal)
PCR (PBMC)  dn ()c dn ()d    
(VWC)       
Virus load (PBMC)       
(VWC)       
MM206 (i.nasal)
PCR (PBMC)   ()c  ()d    
(VWC)       
Virus load (PBMC)   270 56 15 0.3 
(VWC)       
MM207 (i.nasal)
PCR (PBMC)  dn (dn)c dn (dn)d dn  dn 
(VWC)       
Virus load (PBMC)       
(VWC)       
MM158 (control)
PCR (PBMC)       
(VWC)       
Virus load (PBMC)    486 4.5  
(VWC)       
MM164 (control)
PCR (PBMC)       
(VWC)       
Virus load (PBMC)  27 162 9 0.5  
(VWC)       
Note. VWC, vaginal wash cells.
a Proviral DNAs in each samples obtained from all the monkeys were
detected by nested PCR.  or  denotes the detection or no detection
of SHIV-89.6P, respectively. dn represents the detection of SHIV-dn.
b Cell-associated virus load was assayed by coculture with human T
cell line, M8166. Number of virus-producing cells in 1  106 CD8
cell-depleted PBMCs is indicated.  denotes no virus producing cells
in CD8 cell-depleted PBMCs.
c The intestinal lymphocytes were collected from SHIV-dn-inoculated
monkeys by colon biopsy at 1 week postchallenge. The detection of
proviral DNAs in the intestinal lymphocytes is indicated in parentheses.
d The inguinal lymphnodes were collected from SHIV-dn-inoculated
monkeys by biopsy at 2 weeks postchallenge. The detection of proviral
DNAs in the lymphnodes is indicated in parentheses.
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This result might be related to the duration of time be-
tween vaccination and challenge (Connor et al., 1998). In
our study, both monkeys that had been immunized for 52
weeks completely protected against infection of the chal-
lenge virus. Of two monkeys that were challenged at
26 w.p.i., one was also completely protected, but the
other (MM206) resulted in partial protection. Although it
is unclear why the monkeys showed different levels of
protection, having the right immunization periods seemed
important to become immunologically mature. However,
in MM206, unlike in the unimmunized control monkeys,
viral replication was suppressed and CD4 cells counts
did not decline. Although several studies have evaluated
the humoral and cellular immune responses of the mon-
keys to vaccination (Mascola et al., 1999, 2000; Baba et
al., 2000; Joag et al., 1998; Miller et al., 1997), it remains
unclear which kinds of immune response are effective in
preventing viral infection. It is important to evaluate the
protective efficacy against viral infection, including innate
immune responses and adaptive immune responses to a
virus.
Intranasal immunization of an attenuated virus was
effective in eliciting antigen-specific humoral immune
responses in vaginal secretions, while intravenous im-
munization was not so effective, although the two differ-
ent ways of immunization resulted in similar increases in
antigen-specific antibodies in the plasma. These obser-
vations and the finding that antibody responses in vagi-
nal secretions did not correlate with those in the plasma
suggest that the route by which an antigen is adminis-
tered might influence the type of immunity and/or the
sites on which the antigen-specific immune responses
are induced. Recently, several studies have demon-
strated the importance of a local immune response for
protection against virus infection and have emphasized
the importance of immunization for the induction of sys-
temic and mucosal immune responses, especially in
local sites such as the reproductive tract (Crotty et al.,
1999; Joag et al., 1998; Staats et al., 1997; Lehner et al.,
1996). On the other hand, Johnson et al. (1999) demon-
strated that systemic immunization with live-attenuated
SIV could protect against vaginal challenge with SIV-
mac251 and suggested that it induces effective immunity
at multiple sites, including mucosal surfaces. In the
present study, monkeys inoculated intravenously with
SHIV-dn were not completely protected against intravag-
inal infection with SHIV-89.6P, although replication of the
challenge virus was strongly suppressed in these mon-
keys. Thus, a live-attenuated virus can protect against
vaginal challenge of pathogenic virus regardless of the
administration route. However, the type of protection that
is induced might depend on the immunization route:
systemic immunization might limit viral replication at
multiple sites, and mucosal immunization might block
virus entry at mucosal sites. To prove this hypothesis, it
is necessary to examine antigen-specific CTL responses
and cytokine production in mucosal tissues, together
with humoral immune responses examined in this study.
This study has shown that intranasal immunization
with an attenuated virus can result in efficient protection
against intravaginal infection with a heterologous patho-
genic virus. Although various approaches to the devel-
opment of AIDS vaccines are being made throughout the
world, most of these approaches are having difficulty in
FIG. 4. Number of CD4 T cells in PBMCs of the SHIV-dn-immunized monkeys after SHIV-89.6P-intravaginal challenge. (A) MM171 (open circles),
MM187 (open squares), MM206 (open triangles), and MM207 (open diamonds) were intranasally immunized with SHIV-dn before SHIV-89.6P-
intravaginal challenge. (B) MM162 (open circles), MM163 (open squares), MM169 (open triangles), and MM170 (open diamonds) were intravenously
immunized with SHIV-dn. MM158 (closed circles) and MM164 (closed squares) which were unimmunized with SHIV-dn were only intravaginally
inoculated with SHIV-89.6P. Data are expressed as the percentage based on the preinfection values of each monkey.
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protecting against a heterologous pathogenic virus. The
present findings may have important implications for the
design of vaccines used to induce immune responses in
the genital tract.
MATERIALS AND METHODS
Monkeys
Ten sexually mature female rhesus macaques (Ma-
caca mulatta), about 4 kg in weight, were used in this
experiment. All monkeys used in this study were housed
in accordance with regulations approved by the Institu-
tional Animal Care and Use Committee of the Institute for
Virus Research, Kyoto University.
Viruses
In this study, SHIV-dn, obtained by deleting the nef
gene from SHIV-NM-3rN, was used as an attenuated
virus. SHIV-NM-3rN is a chimeric simian and human
immunodeficiency virus, having the envelope gene of
HIV-1 pNL432, and can infect macaque monkeys by
intravenous and intravaginal routes (Igarashi et al., 1997;
Ido et al., 1997). SHIV-dn can also infect macaque mon-
keys when injected intravenously (Ui et al., 1999b). The
virus stock was prepared from supernatants of a human
T cell line, M8166, transfected with pSHIV-dn.
To assess the protective effect of the SHIV-dn induced
immunity, monkeys that had been immunized with
SHIV-dn were challenged with a heterologous patho-
genic virus, SHIV-89.6P. SHIV-89.6P was generated by in
vivo passage of SHIV-89.6 and causes rapid CD4 T cell
depletion and an immunodeficiency syndrome (Reimann
et al., 1996a). SHIV-89.6 had been constructed with env,
tat, rev, and vpu derived from primary isolates of HIV-1.
The amino acid sequences of the envelope gene of
SHIV-89.6P was different by about 12% from that of
SHIV-dn. SHIV-89.6P virus stock was prepared from su-
pernatants of rhesus macaque PBMC cultures which
were infected with the virus strain. Thus, the challenge
virus, SHIV-89.6P, was polyclonal and heterologous virus
stock against SHIV-dn was used in the immunization.
The 50% tissue culture infectious dose (TCID50) of both
the SHIV-dn and the SHIV-89.6P virus stocks was deter-
mined by culture with M8166 cells. These virus stocks
were stored at 80°C until use.
Immunization and viral challenge
Prior to immunization, monkeys were anethetized by
intramuscular injection of ketamine chloride. Four mon-
keys were intranasally immunized three times at 1-day
intervals with 1  106 TCID50 of SHIV-dn. The virus
inoculum was slowly dripped using a disposable syringe
into the right nasal cavity. To compare the effectiveness
of intranasal immunization, four monkeys were intrave-
nously immunized with 1  105 TCID50 of SHIV-dn.
To assess the ability of intranasally induced SHIV-dn
specific immunity to protect against mucosal infection,
four monkeys were intravaginally challenged with the
pathogenic SHIV-89.6P. Two of the monkeys were chal-
lenged at 27 w.p.i. and the other two were challenged at
52 w.p.i. Similarly, four SHIV-dn-intravenously immunized
monkeys were intravaginally challenged with SHIV-89.6P
at 54 w.p.i. Two other monkeys that were not immunized
with SHIV-dn were intravaginally challenged with SHIV-
89.6P as controls. For the challenge, monkeys that were
not in their menstruation period were anesthetized, and
then 1  104 TCID50 of the virus inoculum was infused
once and on the following day infused into the vaginal
cavity using a pediatric feeding catheter.
Sample collection
Blood, vaginal secretions, saliva, and feces were pe-
riodically collected from all monkeys. PBMCs were sep-
arated from heparinized blood by Percoll density centrif-
ugation. VW was obtained from lavage of the vaginal
cavity with 3 ml sterilized PBS using a disposable sy-
ringe, and VWCs were collected by centrifugation. OW
was obtained with a disposable syringe and was diluted
three times with sterilized PBS. FW was obtained by
swabbing the anus with a cotton swab. The obtained FW
was dissolved at 0.02 g/ml in PBS. All plasma and mu-
cosal samples were frozen at 80°C until analysis.
For each of the SHIV-dn-immunized monkeys that
were intravaginally challenged with SHIV-89.6P, intesti-
nal lymphocytes were collected by colon biopsy at
1 w.p.c., and inguinal lymph nodes were collected by
biopsy at 2 w.p.c.
Virus isolation
Infectious cell-associated virus loads were expressed
as the number of virus-producing cells per 1  106 cells
of CD8-depleted PBMCs, as described previously (Ui et
al., 1999b). CD8 cells were depleted from PBMCs ob-
tained from each monkey by mouse anti-human CD8
monoclonal antibody (NU-Ts/c; Nichirei, Japan) and
sheep anti-mouse IgG magnetic beads (Dynabeads
M-450; Dynal A. S., Oslo, Norway). CD8-depleted PBMCs
were diluted threefold serially and cocultured with 1 
106 cells of M8166 for at least 1 month. VWCs were also
cocultured with M8166. Virus recovery was confirmed by
the appearance of syncytium formation and reverse tran-
scriptase (RT) activity in the culture supernatants.
Polymerase chain reaction (PCR)
Cellular DNAs were extracted from PBMCs and VWCs
of the inoculated monkeys by proteinase K as previously
described (Enose et al., 1997). To detect proviral DNAs in
cellular DNAs by nested PCR, 1 g purified cellular DNA
was added to a mixture containing 10 mM Tris–HCl (pH
8.3), 50 mM KCl, 1.5 mM MgCl2, 200 M of each dNTP,
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0.2 M of each primer, and 1.5 unit of AmpliTaq DNA
polymerase (Perkin–Elmer, Norwalk, CT). The amplifica-
tions of DNA fragments (569 bp pSHIV-dn and 612 bp
pSHIV-89.6P) covering the vpr gene of HIV-1 were per-
formed for 30 cycles consisting of denaturation at 94°C
for 60 s, annealing at 58°C for 60 s, and elongation at
72°C for 60 s. The primers for the first amplification were
DF1 (ATCCCACCTGGAAACAGTGGAGAAGAGACA) and
DR3 (TCTCCGCTTCTTCCTGCCATAGGAGATG), and prim-
ers for the second amplification were DF2 (CGGTAAAC-
CACCTACCAAGGGAGCTAATTT) and DR1 (CAAGCAG-
TTTTAGGCTGACTTCCTGGATGC). PCR products were
electrophoretically separated on 1.5% agarose gels and
differentiated by their lengths.
Quantification of plasma viral RNA loads
The viral RNA loads in plasma were determined by
quantitative RT-PCR as described by Suryanarayana et
al. (1998). Total RNAs were prepared from plasma with a
QIAamp viral RNA kit (Qiagen, Germany) according to the
manufacturer’s recommendations, and RT-PCR was per-
formed using a Taqman RT-PCR kit (Perkin–Elmer). To
detect RNA of the challenge virus only, nucleotide se-
quences specific to SHIV-89.6P were amplified using
the primers 89.6p-vpr-F (TGGAAGAAAGACCTCCAGAAA-
ATG) and 89.6p-R131 (CAAGTGCAGTTAGCAAGCGAG-
GAT). To quantify the amplified PCR products in real time,
a labeled probe (89.6p-vpr-T2; FAM-AGGACCACAAAGG-
GAACCATGGGATG-TAMRA) was added to each reaction
mixture containing the RNA equal to 40 l of each
plasma sample. These reactions were performed with a
Prism 7700 Sequence Detector (Applied Biosystems,
Foster City, CA) and analyzed using the manufacturer’s
software. For each run, a standard curve was generated
from duplicate samples at different dilutions whose copy
numbers were known, and the RNA in the plasma sam-
ples were quantified based on the copy number of the
standard samples.
Detection of antibodies to HIV-1 Env protein in
plasma and mucosal secretions
Antibody levels in the plasma were measured by the
passive agglutination (PA) method (Serodia HIV-1/2,
Fujirebio Inc., Tokyo, Japan). The antibody titer was mea-
sured by a fourfold serial dilution of each sample, as
recommended by the manufacturer.
VW, FW, and OW were collected for analysis of anti-
gen-specific antibodies in mucosal secretions. HIV-1
Env-specific antibodies in the plasma and mucosal se-
cretions were detected by the ELISA method. Twenty
microliters of the plasma or 200 l of the secretions was
added to a 96-well plate coated with HIV-1 Env gp160
(Generavia mix; Fujirebio, Japan) and incubated for 30
min at 42°C. After washing the plates three times with
wash buffer, goat anti-monkey IgG antibody (25 ng/ml) or
goat anti-monkey IgA antibody (1 g/ml) (Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD) labeled with
horseradish peroxidase was added to each well and the
mixture incubated for 30 min at 42°C. After washing,
substrate buffer was added to each well. The color re-
action was stopped by addition of 1 N H2SO4 and absor-
bance values were measured at 450 nm. The amounts of
antibody were expressed as the optical density.
Neutralization assay
Neutralizing antibodies were assessed by M8166 cul-
ture, as described previously (Igarashi et al., 1997).
Briefly, plasma and VW samples obtained from monkeys
immunized intranasally with SHIV-dn were heat-inacti-
vated for 30 min at 56°C. A twofold serial dilution of each
sample was incubated with an equal volume of SHIV-
NM3rN or SHIV-89.6P virus stock (100 TCID50) for 90 min
at 37°C. After incubation, the mixtures were cultured with
2  104 M8166 cells in 96-well plates. RT activities in the
culture supernatants were measured at 5 days postin-
fection. The last dilution of each sample at which the
virus replication was inhibited in less than 50% of the
positive samples was defined as the neutralizing titer of
the sample.
Assay of CTL activity
B lymphoblastoid cell lines (B-LCLs) were generated
by transformation of PBMCs isolated from each monkey
with herpes virus papio. The B-LCLs were infected with
recombinant vaccinia virus expressing HIV-1 IIIB Env,
HIV-1 89.6P Env, or SIV Gag (SIVmac239) and then used
as target cells in a chromium (51Cr) release assay. Briefly,
PBMCs obtained from each monkey were stimulated
with ConA and cultured for 7 days in RPMI medium
containing recombinant human IL-2. After cultivation, the
stimulated PBMCs were used as effector cells. Serial
dilutions of effector cells were cultured with 1 104 cells
of 51Cr-labeled autologous target cells dispensed in trip-
licate into each well of 96-well plates. After 5 h, the
culture supernatants of each well were monitored with a
gamma counter. Cytotoxic activity was calculated as the
percentage specific lysis, when effector cells:target cells
ratio was 100:1, using the following formula: (experi-
mental release  spontaneous release)/(total release 
spontaneous release)  100. Total release was deter-
mined by treating the target cells with 2.5% Triton X-100.
Flow cytometry analysis
The frequency of CD4 T lymphocyte subset in PBMCs
was examined by flow cytometry. Lymphocytes were
stained with phycoerythrin (PE)-conjugated mouse anti-
human CD4 monoclonal antibody (NU-TH/I; Nichirei, Ja-
pan) and analyzed on a FACScan (Becton–Dickinson,
Mountain View, CA). Absolute lymphocyte counts in the
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blood were determined with an automated blood cell
counter (F-820; Sysmex, Japan).
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